296 related articles for article (PubMed ID: 28104689)
21. Akebia saponin E, as a novel PIKfyve inhibitor, induces lysosome-associated cytoplasmic vacuolation to inhibit proliferation of hepatocellular carcinoma cells.
Peng P; Jia D; Cao L; Lu W; Liu X; Liang C; Pan Z; Fang Z
J Ethnopharmacol; 2021 Feb; 266():113446. PubMed ID: 33031902
[TBL] [Abstract][Full Text] [Related]
22. Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
Drewry DH; Potjewyd FM; Bayati A; Smith JL; Dickmander RJ; Howell S; Taft-Benz S; Min SM; Hossain MA; Heise M; McPherson PS; Moorman NJ; Axtman AD
J Med Chem; 2022 Oct; 65(19):12860-12882. PubMed ID: 36111834
[TBL] [Abstract][Full Text] [Related]
23. Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial.
Babu S; Nicholson KA; Rothstein JD; Swenson A; Sampognaro PJ; Pant P; Macklin EA; Spruill S; Paganoni S; Gendron TF; Prudencio M; Petrucelli L; Nix D; Landrette S; Nkrumah E; Fandrick K; Edwards J; Young PR
Brain; 2024 Apr; ():. PubMed ID: 38606777
[TBL] [Abstract][Full Text] [Related]
24. PIKfyve, a class III lipid kinase, is required for TLR-induced type I IFN production via modulation of ATF3.
Cai X; Xu Y; Kim YM; Loureiro J; Huang Q
J Immunol; 2014 Apr; 192(7):3383-9. PubMed ID: 24600036
[TBL] [Abstract][Full Text] [Related]
25. Biogenesis of lysosome-related organelles complex-1 (BORC) regulates late endosomal/lysosomal size through PIKfyve-dependent phosphatidylinositol-3,5-bisphosphate.
Yordanov TE; Hipolito VEB; Liebscher G; Vogel GF; Stasyk T; Herrmann C; Geley S; Teis D; Botelho RJ; Hess MW; Huber LA
Traffic; 2019 Sep; 20(9):674-696. PubMed ID: 31314175
[TBL] [Abstract][Full Text] [Related]
26. Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy.
Luttwak E; Smith MR; Zelenetz AD
Expert Opin Pharmacother; 2023; 24(12):1331-1334. PubMed ID: 37294016
[No Abstract] [Full Text] [Related]
27. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
[TBL] [Abstract][Full Text] [Related]
28. Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
Ikonomov OC; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2019 Nov; 383():114771. PubMed ID: 31628917
[TBL] [Abstract][Full Text] [Related]
29. Lysosome enlargement during inhibition of the lipid kinase PIKfyve proceeds through lysosome coalescence.
Choy CH; Saffi G; Gray MA; Wallace C; Dayam RM; Ou ZA; Lenk G; Puertollano R; Watkins SC; Botelho RJ
J Cell Sci; 2018 May; 131(10):. PubMed ID: 29661845
[TBL] [Abstract][Full Text] [Related]
30. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
[TBL] [Abstract][Full Text] [Related]
31. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Alinari L; Quinion C; Blum KA
Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
[TBL] [Abstract][Full Text] [Related]
32. Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis.
Fernandez-Mosquera L; Yambire KF; Couto R; Pereyra L; Pabis K; Ponsford AH; Diogo CV; Stagi M; Milosevic I; Raimundo N
Autophagy; 2019 Sep; 15(9):1572-1591. PubMed ID: 30917721
[TBL] [Abstract][Full Text] [Related]
33. PIKfyve inhibition interferes with phagosome and endosome maturation in macrophages.
Kim GH; Dayam RM; Prashar A; Terebiznik M; Botelho RJ
Traffic; 2014 Oct; 15(10):1143-63. PubMed ID: 25041080
[TBL] [Abstract][Full Text] [Related]
34. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M
Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543
[TBL] [Abstract][Full Text] [Related]
35. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
[TBL] [Abstract][Full Text] [Related]
36. PIKfyve controls dendritic cell function and tumor immunity.
Choi JE; Qiao Y; Kryczek I; Yu J; Gurkan J; Bao Y; Gondal M; Tien JC; Maj T; Yazdani S; Parolia A; Xia H; Zhou J; Wei S; Grove S; Vatan L; Lin H; Li G; Zheng Y; Zhang Y; Cao X; Su F; Wang R; He T; Cieslik M; Green MD; Zou W; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38464258
[TBL] [Abstract][Full Text] [Related]
37. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib and indolent B-cell lymphomas.
Akinleye A; Furqan M; Adekunle O
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):253-60. PubMed ID: 24445187
[TBL] [Abstract][Full Text] [Related]
39. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Forero-Torres A; Ramchandren R; Yacoub A; Wertheim MS; Edenfield WJ; Caimi P; Gutierrez M; Akard L; Escobar C; Call J; Persky D; Iyer S; DeMarini DJ; Zhou L; Chen X; Dawkins F; Phillips TJ
Blood; 2019 Apr; 133(16):1742-1752. PubMed ID: 30803990
[TBL] [Abstract][Full Text] [Related]
40. PIKfyve mediates the motility of late endosomes and lysosomes in neuronal dendrites.
Tsuruta F; Dolmetsch RE
Neurosci Lett; 2015 Sep; 605():18-23. PubMed ID: 26232680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
